Moreover, microbial modulation of bile acid metabolism and downstream activation of farnesoid X receptor (FXR) signaling also influences insulin sensitivity and macrophage phenotype, further linking gut microbial metabolites to systemic immunometabolic networks involved in both metabolic syndrome and tumor progression [45]. The gene discussed is NR1H4; the disease is metabolic syndrome.